LAKEWOOD, Colo.--(BUSINESS WIRE)--Due to public health concerns over the transmission of chikungunya virus (CHIKV) and dengue fever, Terumo BCT will file a submission to the U.S. Food and Drug Administration (FDA) for expanded access use of the Mirasol® Pathogen Reduction Technology System for the treatment of platelets. The expanded access provision is meant to facilitate the availability of promising new therapies and diagnostic devices to patients as early in the development cycle as possible. The Mirasol system is generally used on platelets to reduce pathogens for which no comparable or satisfactory alternative exists.
Help employers find you! Check out all the jobs and post your resume.
